journal article·2023-11-19Open access

Low Relative Handgrip Strength Is Associated with a High Risk of Non-Alcoholic Fatty Liver Disease in Italian Adults: A Retrospective Cohort Study

Samantha Maurotti, Roberta Pujia, Elisa Mazza, Maria Francesca Pileggi, Franco Arturi, Maria Grazia Tarsitano, Tiziana Montalcini, Arturo Pujia, Yvelise Ferro

Applied Sciences· Volume 13· Issue 22

Abstract

Background: Non-alcoholic fatty liver disease (NAFLD) and the presence of low muscle mass (sarcopenia) represent noteworthy health issues. Handgrip strength, a muscle function indicator, is vital for sarcopenia diagnosis. We investigated the link between handgrip strength and hepatic steatosis in Italian adults. Methods: We retrospectively assessed 388 adults (≥50 years), measuring muscle function and hepatic steatosis using a dynamometer and transient elastography. We divided participants into handgrip strength tertiles. Results: 207 had NAFLD. The lowest handgrip strength tertile had a higher NAFLD prevalence (64% vs. 46%, p = 0.02). Tertiles I and II exhibited increased odds of NAFLD in comparison to tertile III, with an odds ratio of 5.30 (95% confidence interval: 2.24–12.57, p < 0.001) and 2.56 (95% confidence interval: 1.17–5.59, p = 0.01), respectively. rHGS predicted NAFLD with an AUC of 0.41 (SE = 0.029, p = 0.003). An rHGS of 1.22 achieved 18% sensitivity and 80% specificity for hepatic steatosis prediction. Conclusion: Low handgrip strength is linked to an increased susceptibility to NAFLD among the Italian population, implying its potential utility in the identification of risk for hepatic steatosis.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Liver Disease Diagnosis and Treatment · Nutrition and Health in Aging · Folate and B Vitamins Research

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Clinical and Experimental Medicine, University Magna Græcia, 88100 Catanzaro, Italy

Department of Medical and Surgical Science, University Magna Græcia, 88100 Catanzaro, Italy

Research Center for the Prevention and Treatment of Metabolic Diseases (CR METDIS), University Magna Græcia, 88100 Catanzaro, Italy

References (84)

Show source-provided references
1. Measurement and interpretation of handgrip strength for research on sarcopenia and osteoporosis10.11005/jbm.2020.27.2.85 ↗
2. Writing Group for the European Working Group on Sarcopenia in Older People 2 (EWGSOP2), and the Extended Group for EWGSOP2. Sarcopenia: Revised European consensus on definition and diagnosis
3. The selection of a screening test for frailty identification in community-dwelling older adults10.1007/s12603-013-0365-4 ↗
4. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International working group on sarcopenia10.1016/j.jamda.2011.01.003 ↗
5. Sarcopenia according to the European Working Group on Sarcopenia in Older People (EWGSOP) versus dynapenia as a risk factor for mortality in the elderly10.1007/s12603-014-0540-2 ↗
6. Malnutrition and impaired muscle strength in patients with Crohn’s disease and ulcerative colitis in remission10.1016/j.nut.2008.03.018 ↗
7. Tak, Y.J., Lee, J.G., Yi, Y.H., Kim, Y.J., Lee, S., Cho, B.M., and Cho, Y.H. (2018). Association of handgrip strength with dietary intake in the Korean population: Findings based on the seventh Korea National Health and Nutrition Examination Survey (KNHANES VII-1), 2016. Nutrients, 10.10.3390/nu10091180 ↗
8. Dynamometer measurements of hand-grip strength predict multiple outcomes10.2466/pms.2001.93.2.323 ↗
9. Prognostic value of grip strength: Findings from the Prospective Urban Rural Epidemiology (PURE) study10.1016/S0140-6736(14)62000-6 ↗
10. Handgrip Strength and Mortality in Elderly Koreans: Evidence from the Korea Longitudinal Study of Ageing10.1177/1010539520937100 ↗
11. Bae, E.-J., Park, N.-J., Sohn, H.-S., and Kim, Y.-H. (2019). Handgrip strength and all-cause mortality in middle-aged and older Koreans. Int. J. Environ. Res. Public. Health, 16.10.3390/ijerph16050740 ↗
12. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: The longitudinal aging study Amsterdam10.1093/gerona/glx245 ↗
13. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes10.1002/hep.28431 ↗
14. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World10.1016/j.cld.2015.10.001 ↗
15. Non-alcoholic fatty liver disease–A global public health perspective10.1016/j.jhep.2018.10.033 ↗
16. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma: A western perspective
17. Suspected nonalcoholic fatty liver disease and mortality risk in a population-based cohort study10.1111/j.1572-0241.2008.02034.x ↗
18. The relationship between 10-year cardiovascular risk calculated using the pooled cohort equation and the severity of non-alcoholic fatty liver disease10.3803/EnM.2016.31.1.86 ↗
19. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis10.1002/hep.29085 ↗
20. Insulin resistance: A contributing factor to age-related muscle mass loss?10.1016/S1262-3636(05)73648-X ↗
21. Chronic low-grade inflammation and age-related sarcopenia10.1097/MCO.0b013e32834dd297 ↗
22. Sarcopenia in non-alcoholic fatty liver disease: Targeting the real culprit?10.1016/j.jhep.2015.05.014 ↗
23. Skeletal muscle myostatin gene expression and sarcopenia in overweight and obese middle-aged and older adults10.1002/crt2.43 ↗
24. Loss-of-function mutation in myostatin reduces tumor necrosis factor alpha production and protects liver against obesity-induced insulin resistance10.2337/db08-0245 ↗
25. Myostatin-deficient mice exhibit reduced insulin resistance through activating the AMP-activated protein kinase signalling pathway10.1007/s00125-011-2079-7 ↗
26. Insulin-like growth factor-1 and non-alcoholic fatty liver disease: A systemic review and meta-analysis10.1007/s12020-019-01982-1 ↗
27. Bian, A., Ma, Y., Zhou, X., Guo, Y., Wang, W., Zhang, Y., and Wang, X. (2020). Association between sarcopenia and levels of growth hormone and insulin-like growth factor-1 in the elderly. BMC Musculoskelet. Disord., 21.10.1186/s12891-020-03236-y ↗
28. Emerging roles of SIRT1 in fatty liver diseases10.7150/ijbs.19370 ↗
29. SIRT1 protein, by blocking the activities of transcription factors FoxO1 and FoxO3, inhibits muscle atrophy and promotes muscle growth10.1074/jbc.M113.489716 ↗
30. SIRT1-dependent mechanisms and effects of resveratrol for amelioration of muscle wasting in NASH mice10.1136/bmjgast-2020-000381 ↗
31. Buscemi, C., Ferro, Y., Pujia, R., Mazza, E., Boragina, G., Sciacqua, A., Piro, S., Pujia, A., Sesti, G., and Buscemi, S. (2021). Sarcopenia and Appendicular Muscle Mass as Predictors of Impaired Fasting Glucose/Type 2 Diabetes in Elderly Women. Nutrients, 13.10.3390/nu13061909 ↗
32. Association of grip strength with non-alcoholic fatty liver disease: Investigation of the roles of insulin resistance and inflammation as mediators10.1038/s41430-020-0591-x ↗
33. Relationship between grip strength and newly diagnosed nonalcoholic fatty liver disease in a large-scale adult population10.1038/srep33255 ↗
34. Relationship between handgrip strength and nonalcoholic fatty liver disease: Nationwide surveys10.1089/met.2018.0077 ↗
35. Lower hand grip strength in older adults with non-alcoholic fatty liver disease: A nationwide population-based study10.18632/aging.102068 ↗
36. Association between muscle strength and advanced fibrosis in non-alcoholic fatty liver disease: A Korean nationwide survey10.1002/jcsm.12598 ↗
37. Cho, J., Lee, I., Park, D.-H., Kwak, H.-B., and Min, K. (2021). Relationships between Socioeconomic Status, Handgrip Strength, and Non-Alcoholic Fatty Liver Disease in Middle-Aged Adults. Int. J. Environ. Res. Public. Health, 18.10.3390/ijerph18041892 ↗
38. Lee, S.B., Kwon, Y.J., Jung, D.H., and Kim, J.K. (2022). Association of Muscle Strength with Non-Alcoholic Fatty Liver Disease in Korean Adults. Int. J. Env. Res. Public. Health, 19.10.3390/ijerph19031675 ↗
39. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease10.1016/j.clnu.2019.04.023 ↗
40. Associations between sarcopenia and nonalcoholic fatty liver disease and advanced fibrosis in the USA10.1097/MEG.0000000000001397 ↗
41. Associations of muscle mass and grip strength with severe NAFLD: A prospective study of 333,295 UK Biobank participants10.1016/j.jhep.2022.01.010 ↗
42. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice10.3748/wjg.v25.i11.1307 ↗
43. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease10.1053/j.gastro.2019.01.042 ↗
44. Transient elastography (FibroScan®) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease-Where do we stand?10.3748/wjg.v22.i32.7236 ↗
45. Utilization of FibroScan in clinical practice10.1007/s11894-014-0372-6 ↗
46. Lipid oxidation assessed by indirect calorimetry predicts metabolic syndrome and type 2 diabetes10.3389/fendo.2018.00806 ↗
47. World Health Organization (2011). Waist Circumference and Waist-Hip Ratio: Report of a WHO Expert Consultation, Geneva, 8-11 December 2008, World Health Organization.
48. Gender difference in handgrip strength of Italian children aged 9 to 10 years10.1186/s13052-016-0226-y ↗
49. Hardy, R., Cooper, R., Aihie Sayer, A., Ben-Shlomo, Y., Cooper, C., Deary, I.J., Demakakos, P., Gallacher, J., Martin, R.M., and McNeill, G. (2013). Body mass index, muscle strength and physical performance in older adults from eight cohort studies: The HALCyon programme. PLoS ONE, 8.10.1371/journal.pone.0056483 ↗
50. Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis10.1016/j.jhep.2016.12.022 ↗
51. Montalcini, T., Pujia, A., Donini, L.M., Frittitta, L., Galvano, F., Natali, A., Pironi, L., Porrini, M., Riso, P., and Rivellese, A.A. (2020). A Call to Action: Now Is the Time to Screen Elderly and Treat Osteosarcopenia, a Position Paper of the Italian College of Academic Nutritionists MED/49 (ICAN-49). Nutrients, 12.10.3390/nu12092662 ↗
52. General Practitioner databaSe NAFLD (GPS-NAFLD) study: Italian regional variability of the NAFLD prevalence rate10.1016/j.dld.2020.12.076 ↗
53. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population
54. Non-alcoholic fatty liver disease in young adult severely obese non-diabetic patients in South Italy10.1159/000087295 ↗
55. Prevalence of and risk factors for hepatic steatosis in Northern Italy10.7326/0003-4819-132-2-200001180-00004 ↗
56. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–203010.1016/j.jhep.2018.05.036 ↗
57. Association between grip strength and non-alcoholic fatty liver disease: A systematic review and meta-analysis10.3389/fmed.2022.988566 ↗
58. A comparison of hepatic steatosis index, controlled attenuation parameter and ultrasound as noninvasive diagnostic tools for steatosis in chronic hepatitis B10.1016/j.dld.2017.03.013 ↗
59. Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index10.3748/wjg.v21.i5.1650 ↗
60. Adverse muscle composition is linked to poor functional performance and metabolic comorbidities in NAFLD10.1016/j.jhepr.2020.100197 ↗
61. Urinary levels of titin-N fragment, a skeletal muscle damage marker, are increased in subjects with nonalcoholic fatty liver disease10.1038/s41598-019-56121-7 ↗
62. The loss of skeletal muscle strength, mass, and quality in older adults: The health, aging and body composition study10.1093/gerona/61.10.1059 ↗
63. Strength, but not muscle mass, is associated with mortality in the health, aging and body composition study cohort10.1093/gerona/61.1.72 ↗
64. Nishikawa, H., Enomoto, H., Yoh, K., Iwata, Y., Sakai, Y., Kishino, K., Ikeda, N., Takashima, T., Aizawa, N., and Takata, R. (2018). Health-related quality of life in chronic liver diseases: A strong impact of hand grip strength. J. Clin. Med., 7.10.3390/jcm7120553 ↗
65. Yoh, K., Nishikawa, H., Enomoto, H., Iwata, Y., Ikeda, N., Aizawa, N., Nishimura, T., Iijima, H., and Nishiguchi, S. (2020). Grip strength: A useful marker for composite hepatic events in patients with chronic liver diseases. Diagnostics, 10.10.3390/diagnostics10040238 ↗
66. Reduced handgrip strength is predictive of poor survival among patients with liver cirrhosis: A sex-stratified analysis10.1111/hepr.13420 ↗
67. Kotoh, Y., Saeki, I., Yamasaki, T., Sasaki, R., Tanabe, N., Oono, T., Matsuda, T., Hisanaga, T., Matsumoto, T., and Hidaka, I. (2020). Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib. Appl. Sci., 10.10.3390/app10165403 ↗
68. Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index10.1111/ajt.15020 ↗
69. A comparison of muscle function, mass, and quality in liver transplant candidates: Results from the functional assessment in liver transplantation (FrAILT) study10.1097/TP.0000000000001232 ↗
70. Sultan, P., Hamilton, M.A., and Ackland, G.L. (2012). Preoperative muscle weakness as defined by handgrip strength and postoperative outcomes: A systematic review. BMC Anesthesiol., 12.10.1186/1471-2253-12-1 ↗
71. Srikanthan, P., Hevener, A.L., and Karlamangla, A.S. (2010). Sarcopenia exacerbates obesity-associated insulin resistance and dysglycemia: Findings from the National Health and Nutrition Examination Survey III. PLoS ONE, 5.10.1371/journal.pone.0010805 ↗
72. The role of GH and IGF-I in mediating anabolic effects of testosterone on androgen-responsive muscle10.1210/en.2010-0802 ↗
73. The role of myostatin in muscle wasting: An overview10.1007/s13539-011-0035-5 ↗
74. AGA technical review on nonalcoholic fatty liver disease10.1053/gast.2002.36572 ↗
75. National Institute for Health and Clinical (2003). Non-Alcoholic Fatty Liver Disease: Assessment and Management, National Institute for Health and Care Excellence (NICE).
76. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease10.1097/HEP.0000000000000323 ↗
77. Practice guidance documents for the diagnosis and management of non-alcoholic fatty liver disease-recent updates and open questions10.21037/hbsn-23-376 ↗
78. Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference10.1053/jhep.2003.50193 ↗
79. Profile of liver enzymes in non-alcoholic fatty liver disease in patients with impaired glucose tolerance and newly detected untreated type 2 diabetes10.4103/2230-8210.163172 ↗
80. Validity criteria for the diagnosis of fatty liver by M probe-based controlled attenuation parameter10.1016/j.jhep.2017.05.005 ↗
81. Application of transient elastography in nonalcoholic fatty liver disease10.3350/cmh.2019.0001n ↗
82. Impact of skin capsular distance on the performance of controlled attenuation parameter in patients with chronic liver disease
83. Effect of skin-capsular distance on controlled attenuation parameter for diagnosing liver steatosis in patients with nonalcoholic fatty liver disease10.1038/s41598-021-94970-3 ↗
84. Oeda, S., Tanaka, K., Oshima, A., Matsumoto, Y., Sueoka, E., and Takahashi, H. (2020). Diagnostic Accuracy of FibroScan and Factors Affecting Measurements. Diagnostics, 10.10.3390/diagnostics10110940 ↗